ClinicalTrials.gg
CompletedNCT03418727Updated Jul 6, 2022Results posted

Dry Eye Disease Study With Brimonidine

A Phase 2 interventional study of Brimonidine and Brimonidine Mono Therapy in Dry Eye, sponsored by Ocugen. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Ocugen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
203rd of 473
84 · median 60
Started
2017
with 15 others
Phase 2
97 of 544
5 open now
Registered
248th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 203rd largest by enrollment of the 473 interventional ones that give a count, is one of 16 that started in 2017, is one of 97 in phase 2, and was the 248th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).

Read the detailed description

Subjects will assess their tolerance to the administration of the study drug, utilizing a Visual Analog Scale (VAS). The VAS is a 100-mm horizontal line with verbal descriptors at either end. The VAS ratings will be completed after administration of the study drug on Day 1 (post-dose), Day 28, Day 56, Day 84, and Day 105. Subjects will place a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older.
  2. Sign and date form approved by the IRB
  3. History of Dry Eye Disease
  4. Objective evidence of DED in at least one eye by having 2 or more of the following 4 signs in the same eye at Screening and Baseline (Day 1) visits:

    i. Conjunctival staining at >/= 1 (out of a possible score of 6 per eye) ii. Corneal staining at >/= 2 (out of a possible score of 15 per eye) iii. Noninvasive Tear Break-Up Time (NITBUT) at \</= 7 seconds iv. Schirmer test at \<10mm in 5 minutes

  5. Symptomatic evidence of DED by having a global symptom score (SANDE) >/= 25 mm at both Screening and Baseline (Day 1) visits
  6. Intraocular pressure (IOP) >/= 5 mmHg and \</= 22 mmHg in each eye
  7. Women who satisfy one of the following:

    1. Are of (WOCP) who are not pregnant or lactating and who are either abstinent or sexually active on an acceptable method of for at least 4 weeks prior to Visit 1 and throughout the study, OR
    2. Are or have undergone a sterilization procedure

Exclusion criteria

Exclusion Criteria:

  1. Allergic to brimonidine, or any similar products, or of brimonidine including benzalkonium chloride (BAK)
  2. Use of contact lenses
  3. Currently receiving brimonidine or other treatment for glaucoma or ocular hypertension or history of glaucoma surgery.
  4. Receiving or have received any experimental or drug or device within 30 days prior to Screening visit
  5. Intraocular pressure \<5 mmHg or >22 mmHg in either eye
  6. Active ocular infection or history of ocular herpetic keratitis
  7. History of neurotrophic keratitis or ocular neuropathic pain
  8. Any history of eyelid surgery or intraocular/ocular surgery within the past 3 months
  9. Punctal occlusion within 3 months prior to Screening visit or during study
  10. Corneal epithelial defect larger than 1 mm2 in either eye
  11. Have active drug/alcohol dependence or abuse history
  12. Are neonates, pregnant/lactating women, children, institutionalized individuals, or others who may be considered vulnerable populations
  13. Received corticosteroid-containing eye drops within the past 7 days or systemic corticosteroids/immunosuppressives within the past 3 months
  14. Received cyclosporine ophthalmic emulsion 0.05% (Restasis®) or lifitegrast ophthalmic solution 5% (Xiidra™) within 30 days prior to Screening visit
  15. In the opinion of Investigator or Study Coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops
  16. Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance to study protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Study Drug Arm #1

    Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks

    Drug: Brimonidine · Drug: Corticosteroid Eye Drop

  • Experimental
    Study Drug Arm #2

    Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks

    Drug: Brimonidine Mono Therapy

  • Placebo comparator
    Control Arm

    Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks

    Drug: sodium carboxymethylcellulose

Interventions

  • Two products delivered in sequence twice daily.

  • DrugBrimonidine Mono Therapy

    Brimonidine given twice daily along with placebo drops

  • Drugsodium carboxymethylcellulose

    Placebo given twice daily.

  • DrugCorticosteroid Eye Drop

    Eye drop to be administered after Brimonidine in treatment arm 1

06

What researchers measure

Primary outcomes

  1. Tolerance of Test Substance Visual Analogue Scale (VAS) Score

    Participants assessed their tolerance to the administration of the study drug, utilizing a VAS. The VAS is a 100-mm horizontal line with verbal descriptors at either end. Participants placed a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).

    Time frame: Days 1, 28, 56, and 84

07

Results

Posted Jul 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlacebo
Started292827
Received at least 1 study treatment292827
Completed282625
Not completed122
Withdrew: Adverse event120
Withdrew: Withdrawal by subject002

Outcome measures

PrimaryTolerance of Test Substance Visual Analogue Scale (VAS) Score

Participants assessed their tolerance to the administration of the study drug, utilizing a VAS. The VAS is a 100-mm horizontal line with verbal descriptors at either end. Participants placed a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).

Time frame:
Days 1, 28, 56, and 84
Reported as:
Mean · score on a scale
Tolerance of Test Substance Visual Analogue Scale (VAS) Score
score on a scaleBrimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlacebo
Day 182.1 (74.5 to 89.8)87.0 (82.2 to 91.9)95.0 (92.3 to 97.7)
Day 2891.1 (86.6 to 95.5)87.4 (82.5 to 92.3)88.2 (82.7 to 93.7)
Day 5692.0 (88.3 to 95.8)85.6 (80.6 to 90.7)91.0 (84.2 to 97.9)
Day 8487.8 (82.2 to 93.5)85.9 (78.6 to 93.1)94.8 (91.6 to 98.1)

Adverse events

Collected over Day 1 (post-dose) up to 105 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine and Corticosteroid Combination Therapy0/29 (0%)1/29 (3.4%)0/29 (0%)
Brimonidine Monotherapy0/28 (0%)0/28 (0%)0/28 (0%)
Placebo0/27 (0%)1/27 (3.7%)0/27 (0%)
Most frequent serious events
Most frequent serious events
EventBrimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlacebo
Knee operationSurgical and medical procedures0/290/281/27
Benign prostatic hyperplasiaReproductive system and breast disorders1/290/280/27

Baseline characteristics

Randomized population including all participants who were randomized to the treatment

Age, Continuous
Age, Continuous(years)Brimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlaceboTotal
Mean62.1 ± 11.4160.4 ± 13.8859.2 ± 14.2360.6 ± 13.09
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlaceboTotal
Female26251869
Male33915
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlaceboTotal
Hispanic or Latino0325
Not Hispanic or Latino29252579
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brimonidine and Corticosteroid Combination TherapyBrimonidine MonotherapyPlaceboTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White28272681
More than one race0000
Unknown or Not Reported0112
08

Study locations

3 sites
  • Chicago Cornea Consultants
    Hoffman Estates, Illinois 60169, United States
  • Brenart Eye Clinic
    Yorkville, Illinois 60560, United States
  • The Eye Institute of Utah
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Mar 2018, 6 months.

Results were first posted in Jul 2022, 4 years 3 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 6 months is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2017
First posted
Feb 1, 2018
StartActual
Sep 6, 2017
Primary completionActual
Mar 29, 2018
CompletionActual
Mar 29, 2018
Results first posted
Jul 6, 2022
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03418727
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Feb 1, 2018
Start date
Sep 6, 2017
Primary completion
Mar 29, 2018
Completion
Mar 29, 2018
Results posted
Jul 6, 2022
Last update
Jul 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion